Back to results
US 2009/0155165 A1Published application
Anti-igf-i receptor antibody
AssigneeImmunoGen, Inc.
InventorsRajeeva SINGH, Daniel J. Tavares, Nancy E. Dagdigian
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeImmunoGen, Inc.
InventorsRajeeva SINGH, Daniel J. Tavares, Nancy E. Dagdigian
Estimating the term…
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.
An isolated antibody or epitope-binding antibody fragment that specifically binds to an insulin-like growth factor-I receptor (IGF-IR), wherein said antibody or antibody fragment is an antagonist of said receptor and is devoid of agonist activity toward said receptor.
An isolated antibody or epitope-binding antibody fragment that specifically binds to an insulin-like growth factor-I receptor (IGF-IR), wherein said antibody or antibody fragment inhibits growth of a cancer cell by greater than about 80% in the presence of serum.
An isolated antibody or epitope-binding antibody fragment that specifically binds to IGF-IR, comprising a heavy chain variable region and a light chain variable region, wherein said heavy chain variable region comprises heavy chain complementarity-determining regions comprising the amino acid sequences of SEQ ID NOs:1-3.
An isolated antibody or epitope-binding antibody fragment that specifically binds to IGF-IR, comprising at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:7.
An isolated antibody or epitope-binding antibody fragment that specifically binds to IGF-IR, comprising at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region comprises the amino acid sequence of SEQ ID NO:7.
An isolated antibody or epitope-binding antibody fragment that specifically binds to IGF-IR, comprising at least one heavy chain variable region and at least one light chain variable region, wherein said light chain variable region has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:8.
An isolated antibody or epitope-binding antibody fragment that specifically binds to IGF-IR, comprising at least one heavy chain variable region and at least one light chain variable region, wherein said light chain variable region comprises the amino acid sequence of SEQ ID NO:8.
An isolated antibody or epitope-binding antibody fragment that specifically binds to an insulin-like growth factor-I receptor (IGF-IR),
An isolated antibody or epitope-binding antibody fragment that specifically binds to an insulin-like growth factor-I receptor (IGF-IR),
An antibody or epitope-binding antibody fragment that specifically binds to an insulin-like growth factor-I (IGF-I) receptor and that has increased affinity for IGF-I receptor compared to a control antibody, said antibody or antibody fragment prepared by:
A method for inducing apoptosis in a cell comprising contacting said cell with the murine antibody EM164 (ATCC deposit number PTA-4457) or an epitope-binding fragment thereof that specifically binds to an insulin-like growth factor-I receptor, wherein said antibody or epitope-binding fragment is an antagonist of said receptor and is devoid of agonist activity toward said receptor.
A method for inducing apoptosis in a cell comprising contacting said cell with the humanized or resurfaced antibody EM164 or an epitope-binding fragment thereof that specifically binds to an insulin-like growth factor-I receptor, wherein said antibody or fragment is an antagonist of said receptor and is devoid of agonist activity toward said receptor.
An isolated antibody or epitope-binding antibody fragment that specifically binds to an insulin-like growth factor-I receptor (IGF-IR), wherein said antibody or antibody fragment is capable of inhibiting the growth of a cancer cell by greater than about 80% in the presence of a growth stimulant selected from the group consisting of serum, insulin-like growth factor-I and insulin-like growth factor-II, and wherein said antibody or antibody fragment is devoid of agonist activity toward said receptor.
An isolated antibody or epitope-binding antibody fragment that specifically binds to IGF-IR, comprising at least one heavy chain variable region and at least one light chain variable region, wherein sequentially arranged complementarity-determining regions of the heavy chain variable region are:
A isolated antibody or fragment thereof that specifically binds to IGF-IR, comprising at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region comprises three complementarities-determining regions comprising the amino acid sequences of SEQ ID NOS:1, 54 and 3, and wherein said light chain variable region comprises three complementarity-determining regions comprising the amino acid sequences of SEQ ID NOS:4-6.
An antibody or fragment thereof, comprising a heavy chain variable region having a sequence selected from the group consisting of
An antibody or fragment thereof, comprising a heavy chain variable region having a sequence selected from the group consisting of
An isolated humanized antibody or epitope-binding antibody fragment that specifically binds to IGF-IR, comprising at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region comprises three complementarity-determining regions comprising the amino acid sequences of SEQ ID NOS:1-3, respectively, and wherein said light chain variable region comprises three complementarity-determining regions comprising the amino acid sequences of SEQ ID NOS:4-6.
An isolated humanized antibody or epitope-binding antibody fragment that specifically binds to IGF-IR, comprising a light chain variable region having a sequence selected from the group consisting of
An isolated humanized antibody or epitope-binding antibody fragment that specifically binds to IGF-IR, comprising a heavy chain variable region having the sequence of SEQ ID NO:88.
An antibody or fragment thereof, comprising a light chain variable region having a sequence selected from the group consisting of
Dependencies are inferred from the claim text.